Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?

3 days ago 6

Soumya Eswaran

Tue, November 18, 2025 astatine 6:31 AM CST 3 min read

Artisan Partners, an concern absorption company, released its “Artisan Small Cap Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. Global equities proceed to rally successful the 3rd quarter, the play with double-digit YTD gains. Major US indices similar Russell 1000®, Russell Midcap®, and Russell 2000® reached grounds highs successful the period. In the quarter, the fund’s Investor Class money ARTSX returned 8.69%, Advisor Class money APDSX posted a instrumentality of 8.75%, and Institutional Class money APHSX returned 8.73%, compared to a instrumentality of 12.19% for the Russell 2000 Growth Index. In addition, you tin cheque the fund’s apical 5 holdings to find retired its champion picks for 2025.

In its third-quarter 2025 capitalist letter, Artisan Small Cap Fund highlighted stocks specified arsenic Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL). Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is simply a biopharmaceutical company. The one-month instrumentality of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) was 28.70%, and its shares gained 76.15% of their worth implicit the past 52 weeks. On November 17, 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) banal closed astatine $553.42 per share, with a marketplace capitalization of $12.569 billion.

Artisan Small Cap Fund stated the pursuing regarding Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) successful its 3rd 4th 2025 capitalist letter:

"We besides added to Loar Holdings, Installed Building Products and Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) during the quarter. Madrigal Pharmaceuticals is simply a commercial-stage biotech institution focused connected treating metabolic dysfunction-associated steatohepatitis (MASH)—a superior liver illness with important unmet need— done its pb drug, Rezdiffra™. As the archetypal and lone FDA-approved attraction for MASH with mean to precocious fibrosis (F2–F3), Rezdiffra offers clinically meaningful efficacy and a favorable information profile. During the quarter, we accrued our presumption successful Madrigal Pharmaceuticals to a tiny CropSM, driven by the palmy motorboat of its F2–F3 therapy and effectual execution successful pricing negotiations with insurers. With an progressive income unit and increasing marketplace presence, we person expanding assurance successful Madrigal’s quality to service the F4 MASH (compensated cirrhosis) diligent population, pending aboriginal support of its therapy for that stage."

Is Madrigal Pharmaceuticals, Inc. (MDGL) The Most Expensive Stock Insiders Are Dumping In March?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 47 hedge money portfolios held Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) astatine the extremity of the 2nd quarter, up from 46 successful the erstwhile quarter. In the 3rd 4th of 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported nett income of $287 million, up 35% quarter-over-quarter. While we admit the imaginable of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.